Subscribe To
Mersana therapeutics to present at upcoming investor conferences
CAMBRIDGE, Mass., May 24, 2023 (GLOBE NEWSWIRE) — Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on d...
May 24, 2023, 12:00 pm
Exact sciences positioned for a solid year after ‘impressive' 1q, broker says
Exact Sciences (NASDAQ:EXAS) Corporation earned a price target raise from Canaccord Genuity (TSX:CF, LSE:CF) after the molecular diagnostics company ...
May 16, 2023, 2:43 pm
Bridgebio pharma to present updated data from its bbp-812 canavan disease gene therapy program at the 2023 american society of gene and cell therapy (asgct) annual meeting
PALO ALTO, Calif., May 15, 2023 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage ...
May 15, 2023, 11:30 am
Bridgebio pharma to present updated data from its bbp-812 canavan disease gene therapy program at the 2023 american society of gene and cell therapy (asgct) annual meeting
PALO ALTO, Calif., May 15, 2023 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage ...
May 15, 2023, 7:30 am
Merck to present extensive new research demonstrating significant progress in the treatment of certain earlier stage cancers and in advancing broad oncology pipeline at 2023 asco annual meeting
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck ASCO Curtain Raiser....
May 15, 2023, 6:45 am
Viracta therapeutics to present at the rbc capital markets global healthcare conference
SAN DIEGO, May 11, 2023 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company focused on the treatment and preve...
May 11, 2023, 4:05 pm
Hookipa pharma reports first quarter 2023 financial results and recent business highlights
HOOKIPA on track to report Phase 2 data on HB-200 for head and neck cancer in combination with pembrolizumab in 2Q 2023 Phase 1 clinical trials initia...
May 11, 2023, 11:01 am
Glycomimetics: an asymmetric opportunity that could change hematology
Rarely, a developmental biotech comes along with new chemistry that potentially becomes curative via transplantation. Blood ...
May 10, 2023, 12:20 pm
Cti biopharma skyrockets on acquisition by sobi
CTI BioPharma shares added almost 85% on the news that the company would be acquired by Stockholm-based hematology and immunology leader Swedish Orpha...
May 10, 2023, 11:13 am
Swedish orphan biovitrum to acquire cti biopharma in a deal valued at $1.7 billion
Swedish Orphan Biovitrum AB SE:SOBI on Wednesday announced that it has entered into an agreement to acquire U.S.-based CTI BioPharma Corp. CTIC in a d...
May 10, 2023, 2:26 am
Aim immunotech to discuss first quarter 2023 financial results on may 16, 2023 and host conference call and webcast
OCALA, Fla., May 09, 2023 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company foc...
May 9, 2023, 12:50 pm
Blueprint is well-positioned to capitalize on ism market (maintain 'buy')
Blueprint Medicines focuses on developing precision therapies for genomically defined cancers and blood...
May 9, 2023, 2:28 am
Olema oncology announces upcoming poster presentation at the 2023 esmo breast cancer annual congress
SAN FRANCISCO, May 08, 2023 (GLOBE NEWSWIRE) — Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage bio...
May 8, 2023, 11:06 am
Prophase labs’ linebacker-1 cancer therapeutic shows promising mechanisms of action as both a mono-therapy and co-therapy in preclinical studies attacking a range of hard-to-treat cancers, including l
Garden City, NY, May 03, 2023 (GLOBE NEWSWIRE) — ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase”), a next-generation biotech, genomics and diagno...
May 3, 2023, 12:30 pm
Delcath systems to host first quarter 2023 results
NEW YORK , May 3, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary an...
May 3, 2023, 8:30 am
Can-fite biopharma spikes on pancreatic cancer inhibition finding
Can-Fite BioPharma Ltd. NYSEAMERICAN: CANF is an Israel-based biotechnology firm that develops small-molecule therapeutic treatments for ...
May 2, 2023, 1:12 pm
Cti biopharma to report first quarter 2023 financial results and provide corporate update on thursday, may 11, 2023
SEATTLE , May 1, 2023 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC), a commercial biopharmaceutical company focused on the development and commer...
May 1, 2023, 4:46 pm
Predicine to introduce predicinealert™ mrd assay and present two ctdna studies in genitourinary cancers at aua 2023 annual meeting
HAYWARD, Calif., April 28, 2023 (GLOBE NEWSWIRE) — Predicine, a global molecular insights company, announced today that it will present two studies ...
April 28, 2023, 9:42 pm
Hillstream biopharma announces pricing of public offering
BRIDGEWATER, N.J., April 27, 2023 (GLOBE NEWSWIRE) — Hillstream BioPharma, Inc. (Nasdaq: HILS) (“Hillstream” or the “Company”), a biotechnol...
April 28, 2023, 1:50 am
Qualigen therapeutics, inc. receives nasdaq notice regarding delayed form 10-k filing
CARLSBAD, Calif., April 21, 2023 (GLOBE NEWSWIRE) — Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), a diversified l...
April 21, 2023, 9:46 pm